Application of nanoliposome as contrast agents for magnetic resonance imaging technique

Liposomes, nano-sized vesicles primarily comprising phospholipids and cholesterol, have emerged as pivotal tools in medical imaging, notably in magnetic resonance imaging (MRI), due to their biocompatibility and ability to encapsulate diverse molecules. Tailorable properties like size, surface charge, and encapsulation capacity make liposomes ideal for targeted delivery of imaging agents and drugs to specific tissues, improving pharmacokinetics. As MRI contrast agent (CA) carriers, liposomes encapsulate gadolinium, mitigating toxicity and boosting relaxivity and circulation times. Functionalization with targeting ligands and stimuli-responsive designs enhances their controlled release and targeted delivery capabilities, crucial for cancer imaging and therapy. Benefits include reduced toxicity, prolonged circulation, targeted delivery, enhanced bioavailability, and potential for multimodal imaging. Challenges remain, such as stability, clearance, and manufacturing intricacies, requiring further research. Nonetheless, liposomal MRI CAs hold promise for enhancing diagnostic precision and therapeutic effectiveness in oncology and neurology, offering a robust pathway for future biomedical advancements. Addressing existing limitations could unlock their full potential in improving patient care and outcomes. image